Skip to content

Addiction: all studies

Page 223 of 857: studies 2,221 to 2,230 of 8,563, newest first. Back to the addiction overview

Research

Delusion as embodied emotion: a qualitatively driven, multimethod study of first-episode psychosis in the UK.

The Lancet Psychiatry February 1, 2026 Rosa Ritunnano, Jeannette Littlemore, Barnaby Nelson et al. 8 citations

Delusions in psychosis involve complex and dynamic experiential, affective, cognitive, behavioural, and interpersonal alterations. Their pattern of emergence during the early stages of illness remains poorly understood and the origin of their thematic content unclear. Phenomenological accounts have emphasised alterations of selfhood and reality experience in delusion formation but have not...

The hippocampus as a central hub in ketamine's antidepressant action: from molecules to circuit rewiring.

Neuropsychopharmacology February 1, 2026 Dongsun Park, Gwangho Lee, Bokyum Kim et al. 1 citation

Ketamine has emerged as a rapid-acting antidepressant that challenges classical monoaminergic frameworks and highlights the importance of synaptic and circuit-level plasticity in mood regulation. This review examines the hippocampus as a key site through which ketamine exerts both rapid and sustained antidepressant effects. We synthesize evidence showing that ketamine enhances hippocampal...

Ayahuasca modulation of traumatic-like fear memories requires infralimbic cortex BDNF-dependent mechanisms in rats.

European Neuropsychopharmacology February 1, 2026 Isabel Werle, Francisco S Guimarães, Rafael G. Dos Santos et al.

Rodent studies have shown that psychedelic drugs can enhance fear extinction. However, investigations to date have relied on normative aversive conditioning procedures, which limit their relevance to trauma-related memories, as these tend to be overgeneralized and resistant to extinction. Fear extinction depends on activity and plasticity within the infralimbic (IL) region of the medial...

Contemplating versus having used psychedelics in bipolar disorder - What makes the difference?

Journal of Affective Disorders February 1, 2026 Lauren N Vale, Maya Ibrahim, Leonardo Fávaro-pereira et al. 1 citation

In recent years psychedelics have gained popularity and potential promise in the field of mental health, but for patients diagnosed with bipolar disorder (BD), fears of emerging manic or psychotic symptoms have caused investigators to exclude them from psychedelic research. In this observational study, we explore the motivations, expectations, and personality characteristics of individuals with...

DOI: 10.1016/j.jad.2025.120437 (opens in new tab) Full text (opens in new tab) Attitudes towards psychedelics Bipolar disorder Mental health treatment Mood disorders +1

Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy.

Brain and Behavior February 1, 2026 Rachel Ham, John Gardner, Adrian Carter et al. 1 citation

Although commonly used in psychedelic-assisted therapy, the role of therapeutic touch remains loosely defined and ethically sensitive. Gaining insight into how participants experience and interpret touch during psychedelic sessions is essential for informing safe and effective clinical practice. Participants were sampled from a large randomized clinical trial of psilocybin-assisted therapy that...

Neural correlates of ibogaine: Evidence from functional neuroimaging of military veterans

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging February 1, 2026 Malvika Sridhar, Azeezat Azeez, Andrew Geoly et al.

BackgroundIbogaine was recently found to result in significant functional improvements in treating the sequelae of traumatic brain injury (TBI) among Special Operations Forces veterans (SOVs). In the current study, we used multimodal neuroimaging to elucidate the neural correlates of ibogaine in 30 male SOVs who received ibogaine treatment.MethodsArterial spin labeling and blood oxygen...

DOI: 10.1016/j.bpsc.2026.02.001 (opens in new tab) Functional neuroimaging Neural activity Functional brain imaging Functional connectivity +2

Psychedelics and the Extracellular Matrix: Rewiring Neuroplasticity and Metaplasticity for Next-Generation Psychiatric Therapies

Biological Psychiatry February 1, 2026 Jin Zhang, Cong Lin, Xinyou Lv et al. 1 citation

Classic psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT), have emerged as potent modulators of neuroplasticity and metaplasticity in the adult brain, offering novel therapeutic strategies for neuropsychiatric disorders. Recent findings reveal that beyond their transient psychotropic effects, these compounds activate serotonin 5-HT2A receptors...

On biological and artificial consciousness: A case for biological computationalism.

Neuroscience & Biobehavioral Reviews February 1, 2026 Borjan Milinkovic, Jaan Aru 7 citations

The rapid advances in the capabilities of Large Language Models (LLMs) have galvanised public and scientific debates over whether artificial systems might one day be conscious. Prevailing optimism is often grounded in computational functionalism: the assumption that consciousness is determined solely by the right pattern of information processing, independent of the physical substrate. Opposing...

DOI: 10.1016/j.neubiorev.2025.106524 (opens in new tab) Full text (opens in new tab) Artificial consciousness Artificial intelligence Artificial neural networks Biological computation +8

The Emerging Crisis in Non-Prescribed Ketamine Use: A Rapid Attenuation of Depression in Face of Abuse and "Chill-out" or Escapism Drug.

Substance Use & Misuse February 1, 2026 Kai-Uwe Lewandrowski, Kenneth Blum, Sergio Schmidt et al.

Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines...

Clinical benefits and considerations of dextromethorphan and bupropion administered separately for managing depression: A case report.

Mental Health Clinician February 1, 2026 Parna Haghparast, Busuyi Olotu, Carol Yuan

MDD can affect anyone regardless of age, and it often starts during late teens or early adulthood. Although some patients with MDD have an adequate response to medications, only approximately 50% respond to the first treatment, and approximately 30% do not achieve remission despite multiple interventions. Several strategies exist for treating patients who have failed multiple first-line agents,...